804 related articles for article (PubMed ID: 1675655)
1. Trispecific F(ab')3 derivatives that use cooperative signaling via the TCR/CD3 complex and CD2 to activate and redirect resting cytotoxic T cells.
Tutt A; Stevenson GT; Glennie MJ
J Immunol; 1991 Jul; 147(1):60-9. PubMed ID: 1675655
[TBL] [Abstract][Full Text] [Related]
2. Bispecific F(ab'gamma)3 antibody derivatives for redirecting unprimed cytotoxic T cells.
Tutt A; Greenman J; Stevenson GT; Glennie MJ
Eur J Immunol; 1991 Jun; 21(6):1351-8. PubMed ID: 1828423
[TBL] [Abstract][Full Text] [Related]
3. Activation and preferential expansion of rat cytotoxic (CD8) T cells in vitro and in vivo with a bispecific (anti-TCR alpha/beta x anti-CD2) F(ab')2 antibody.
Tutt AL; Reid R; Wilkins BS; Glennie MJ
J Immunol; 1995 Sep; 155(6):2960-71. PubMed ID: 7673714
[TBL] [Abstract][Full Text] [Related]
4. Differential T cell hyporesponsiveness induced by in vivo administration of intact or F(ab')2 fragments of anti-CD3 monoclonal antibody. F(ab')2 fragments induce a selective T helper dysfunction.
Hirsch R; Archibald J; Gress RE
J Immunol; 1991 Oct; 147(7):2088-93. PubMed ID: 1833451
[TBL] [Abstract][Full Text] [Related]
5. Activation of human cytolytic cells through CD2/T11. Comparison of the requirements for the induction and direction of lysis of tumor targets by T cells and NK cells.
Scott CF; Bolender S; McIntyre GD; Holldack J; Lambert JM; Venkatesh YP; Morimoto C; Ritz J; Schlossman SF
J Immunol; 1989 Jun; 142(11):4105-12. PubMed ID: 2565930
[TBL] [Abstract][Full Text] [Related]
6. Activation of T cells by cross-linking an anti-CD3 antibody with a second anti-T cell antibody: mechanism and subset-specific activation.
Walker C; Bettens F; Pichler WJ
Eur J Immunol; 1987 Jun; 17(6):873-80. PubMed ID: 2439351
[TBL] [Abstract][Full Text] [Related]
7. Valency of CD3 binding and internalization of the CD3 cell-surface complex control T cell responses to second signals: distinction between effects on protein kinase C, cytoplasmic free calcium, and proliferation.
Ledbetter JA; June CH; Martin PJ; Spooner CE; Hansen JA; Meier KE
J Immunol; 1986 Jun; 136(11):3945-52. PubMed ID: 3084650
[TBL] [Abstract][Full Text] [Related]
8. Bispecific F (ab')2 monomer prepared with anti-CD3 and anti-tumor monoclonal antibodies is most potent in induction of cytolysis of human T cells.
Nitta T; Yagita H; Azuma T; Sato K; Okumura K
Eur J Immunol; 1989 Aug; 19(8):1437-41. PubMed ID: 2528460
[TBL] [Abstract][Full Text] [Related]
9. Human resting B lymphocytes can serve as accessory cells for anti-CD2-induced T cell activation.
Hirokawa M; Gray JD; Takahashi T; Horwitz DA
J Immunol; 1992 Sep; 149(6):1859-66. PubMed ID: 1355500
[TBL] [Abstract][Full Text] [Related]
10. Induction of lysis by T cell receptor gamma delta+/CD3+ T lymphocytes via CD2 requires triggering via the T11.1 epitope only.
Goedegebuure PS; Segal DM; Braakman E; Vreugdenhil RJ; Van Krimpen BA; Van de Griend RJ; Bolhuis RL
J Immunol; 1989 Mar; 142(6):1797-802. PubMed ID: 2466076
[TBL] [Abstract][Full Text] [Related]
11. Heterodimeric complex formation with CD8 and TCR by bispecific antibody sustains paracrine IL-2-dependent growth of CD3+ CD8+ T cells.
De Lau WB; Boom SE; Heije K; Griffioen AW; Braakman E; Bolhuis RL; Tax WJ; Clevers H; Bast BJ
J Immunol; 1992 Sep; 149(6):1840-6. PubMed ID: 1387662
[TBL] [Abstract][Full Text] [Related]
12. Engineering a humanized bispecific F(ab')2 fragment for improved binding to T cells.
Rodrigues ML; Shalaby MR; Werther W; Presta L; Carter P
Int J Cancer Suppl; 1992; 7():45-50. PubMed ID: 1428403
[TBL] [Abstract][Full Text] [Related]
13. Delivery of saporin to human B-cell lymphoma using bispecific antibody: targeting via CD22 but not CD19, CD37, or immunoglobulin results in efficient killing.
Bonardi MA; French RR; Amlot P; Gromo G; Modena D; Glennie MJ
Cancer Res; 1993 Jul; 53(13):3015-21. PubMed ID: 7686448
[TBL] [Abstract][Full Text] [Related]
14. Induction and blocking of cytolysis in CD2+, CD3- NK and CD2+, CD3+ cytotoxic T lymphocytes via CD2 50 KD sheep erythrocyte receptor.
Bolhuis RL; Roozemond RC; van de Griend RJ
J Immunol; 1986 Jun; 136(11):3939-44. PubMed ID: 3084649
[TBL] [Abstract][Full Text] [Related]
15. Anti-CD3 x anti-tumor F(ab')2 bifunctional antibody activates and retargets tumor-infiltrating lymphocytes.
Chapoval AI; Nelson H; Thibault C
J Immunol; 1995 Aug; 155(3):1296-303. PubMed ID: 7636196
[TBL] [Abstract][Full Text] [Related]
16. Target cell-induced T cell activation with bi- and trispecific antibody fragments.
Jung G; Freimann U; Von Marschall Z; Reisfeld RA; Wilmanns W
Eur J Immunol; 1991 Oct; 21(10):2431-5. PubMed ID: 1655465
[TBL] [Abstract][Full Text] [Related]
17. Anti-CD3 and phorbol myristate acetate regulation of MHC unrestricted T cell cytotoxicity. Lack of a requirement for CD3/T cell receptor complex expression during tumor cell lysis.
Thiele DL; Patel SS; Lipsky PE
J Immunol; 1988 May; 140(9):3253-60. PubMed ID: 2966209
[TBL] [Abstract][Full Text] [Related]
18. Modulation of lymphokine release and cytolytic activities by activating peripheral blood lymphocytes via CD2.
Valentin H; Groux H; Gelin C; Chretien I; Bernard A
J Immunol; 1990 Feb; 144(3):875-82. PubMed ID: 1967277
[TBL] [Abstract][Full Text] [Related]
19. Apoptosis of activated CD8+/CD57+ T cells is induced by some combinations of anti-CD2 mAb.
Rouleau M; Bernard A; Lantz O; Vernant JP; Charpentier B; Senik A
J Immunol; 1993 Oct; 151(7):3547-56. PubMed ID: 7690806
[TBL] [Abstract][Full Text] [Related]
20. Characterization of the CD4+ and CD8+ tumor infiltrating lymphocytes propagated with bispecific monoclonal antibodies.
Wong JT; Pinto CE; Gifford JD; Kurnick JT; Kradin RL
J Immunol; 1989 Nov; 143(10):3404-11. PubMed ID: 2509557
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
